James C. Mulloy, PhD

Professor, UC Department of Pediatrics

Phone 513-636-1844

Fax 513-636-3768

Email james.mulloy@cchmc.org

BA: St. Anselm College, Manchester, New Hampshire, 1986.

MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1989.

PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1992.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G. Down-regulation of RUNX1/CBFβ by MLL fusion proteins enhances HSC self-renewal. Blood. 2014 Jan 21. In press.

Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line. Leukemia. 2013 Dec 11. In press.

Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. Journal of Clinical Investigation. 2014 Jan 2;124(1):222-36.

Mulloy JC. A new inducible model for t(8;21) AML. EMBO Mol Med. 2013 Dec;5(12):1795-7.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. PP2A-Activating Drugs (PADs) selectively eradicate TKI-resistant Ph+ leukemic stem cells. Journal of Clinical Investigation. 2013 Oct 1;123(10):4144-4157.

Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JC. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. Journal of Clinical Investigation. 2013 Sep 3;123(9):3876-88.

Araten DJ, Krejci O, Ditata K, Wunderlich M, Sanders KJ, Zamechek L, Mulloy JC. The rate of spontaneous mutation in human myeloid cells. Mutation Research. 2013 Sep;749(1-2):49-57.

Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci. U S A. 2012;109(47):19397-402.

Conferring in vivo metabolic resistance to a highly selective anti-AML agent. Co-Investigator. National Institutes of Health R21 NCI (Merino/Mulloy). Apr 2014 - Mar 2016.

Origin and progression of Myelosdysplastic syndrome in patients with Bone Marrow Failure Disorders. Co-Investigator. Center for Clinical and Translational Science and Training (Mehta/Mulloy/Cancelas). Jul 2014 - Jun 2015.

Therapeutic Targeting of LARG-RhoA signaling in childhood leukemia. Co-Principal Investigator. Alex's Lemonade Stand (Zheng/Mulloy). Jul 2013 - Jun 2015.

Targeting Cdc42 in leukemia stem cells. Co-Principal Investigator. National Cancer Institute. Apr 2010 - Mar 2015. #1R01CA150547-01. 

Rac Signaling in MLL Leukemia. Principal Investigator. Leukemia and Lymphoma Society. Jul 2010 - Jun 2015.

Cincinnati Center of Excellence in Molecular Hematology. Co-Director, Animal Core. National Institutes of Health. Sep 2010 – Jul 2015. # P30 DK090971.

Genotype and phenotype of chemoresistant AML. Principal Investigator. NIH, NCI. Mar 2013 - Feb 2015. R21 CA168369

LSC mobilization and differentiation therapy. Co-Principal Investigator. Hyundai Hope On Wheels! (Mulloy/Mizukawa). Sep 2013 - Aug 2015.